

NASH/MASH Treatment Market - 2025-2033

<https://marketpublishers.com/r/N60C31F0A86EEN.html>

Date: March 2026

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: N60C31F0A86EEN

Abstracts

The NASH/MASH Treatment Market was valued at US\$ 8.13 billion in 2025 and is anticipated to reach US\$ 33.02 billion by 2033, at a CAGR of 0.1755 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the NASH/MASH Treatment Market.

This report delivers a comprehensive overview of the NASH/MASH Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding NASH/MASH Treatment Market. The NASH/MASH Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

NASH/MASH Treatment Market Scope:

By Drug

Resmetirom (Rezdiffra)

Lanifibranor

Semaglutide

Survodutide

Pegozafermin

Efruxifermin

Denifanstat

Others

By Stage

Stage 0-1

Stage 2-3

Stage 4

By Age-Group

Pediatrics

Adults

Geriatrics

By Gender

Male

Female

Key Players

Madrigal Pharmaceuticals

Novo Nordisk A/S

Boehringer Ingelheim International GmbH.

89bio, Inc.

Inventiva.

CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD

Sagimet Biosciences.

Akero Therapeutics, Inc. Similar data will be provided for each market player.
LIST NOT EXHAUSTIVE

Major Highlights

This report delivers a comprehensive overview of the NASH/MASH Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding NASH/MASH Treatment Market. The NASH/MASH Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2025–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the

latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Drug
- 3.2. Snippet by Stage
- 3.3. Snippet by Age Group
- 3.4. Snippet by Gender
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising prevalence of underlying conditions
 - 4.1.1.2. Rising awareness on MASH
 - 4.1.2. Restraints
 - 4.1.2.1. Limited availability of approved drugs
 - 4.1.2.2. Patient compliance issues
 - 4.1.2.3. XX
 - 4.1.3. Opportunities
 - 4.1.3.1. Emerging drugs
 - 4.1.3.2. Partnerships and collaborations
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Epidemiology
- 5.3. Pricing Analysis
- 5.4. Pipeline Analysis
- 5.5. Patent Analysis

5.6. Regulatory Analysis

6. BY DRUG

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

6.1.2. Market Attractiveness Index, By Drug

6.2. Resmetirom (Rezdiffra)*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Lanifibranor

6.4. Semaglutide

6.5. Survodutide

6.6. Pegozafermin

6.7. Efruxifermin

6.8. Denifanstat

6.9. Others

7. BY STAGE

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage

7.1.2. Market Attractiveness Index, By Stage

7.2. Stage 0-1*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.3. Stage 2-3

7.4. Stage

8. BY AGE-GROUP

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group

8.1.2. Market Attractiveness Index, By Age-Group

8.2. Pediatrics*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

8.3. Adults

8.4. Geriatrics

9. BY GENDER

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

9.1.2. Market Attractiveness Index, By Gender

9.2. Male*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

9.3. Female

10. BY REGION

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

10.1.2. Market Attractiveness Index, By Region

10.2. North America

10.2.1. Introduction

10.2.2. Key Region-Specific Dynamics

10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage

10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group

10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.2.7.1. U.S.

10.2.7.2. Canada

10.2.7.3. Mexico

10.3. Europe

10.3.1. Introduction

10.3.2. Key Region-Specific Dynamics

10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage

10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group

10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.3.7.1. Germany

10.3.7.2. U.K.

10.3.7.3. France

10.3.7.4. Spain

10.3.7.5. Italy

10.3.7.6. Rest of Europe

10.4. South America

10.4.1. Introduction

10.4.2. Key Region-Specific Dynamics

10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage

10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group

10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.4.7.1. Brazil

10.4.7.2. Argentina

10.4.7.3. Rest of South America

10.5. Asia-Pacific

10.5.1. Introduction

10.5.2. Key Region-Specific Dynamics

10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage

10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group

10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

10.5.7.1. China

10.5.7.2. India

10.5.7.3. Japan

10.5.7.4. South Korea

10.5.7.5. Rest of Asia-Pacific

10.6. Middle East and Africa

10.6.1. Introduction

10.6.2. Key Region-Specific Dynamics

10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug

10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage

10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age-Group

10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Gender

11. COMPETITIVE LANDSCAPE

11.1. Competitive Scenario

11.2. Market Positioning/Share Analysis

11.3. Mergers and Acquisitions Analysis

12. COMPANY PROFILES

12.1. Madrigal Pharmaceuticals*

12.1.1. Company Overview

12.1.1.1. Product Portfolio

12.1.1.2. Product Description

12.1.1.3. Product Key Performance Indicators (KPIs)

12.1.1.4. Historic and Forecasted Product Sales

12.1.1.5. Product Sales Volume

12.1.2. Financial Overview

12.1.2.1. Company Revenue's

12.1.2.2. Geographical Revenue Shares

12.1.2.3. Revenue Forecasts

12.1.3. Key Developments

12.1.3.1. Mergers & Acquisitions

12.1.3.2. Key Product Development Activities

12.1.3.3. Regulatory Approvals etc.

12.1.3.4. SWOT Analysis

12.2. Novo Nordisk A/S

12.3. Boehringer Ingelheim International GmbH.

12.4. 89bio, Inc.

12.5. Inventiva.

12.6. CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD

12.7. Sagimet Biosciences.

12.8. Akero Therapeutics, Inc. * Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. APPENDIX

13.1. About Us and Services

13.2. Contact Us

I would like to order

Product name: NASH/MASH Treatment Market - 2025-2033

Product link: <https://marketpublishers.com/r/N60C31F0A86EEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N60C31F0A86EEN.html>